CmAbs-immune effector molecule fusion (Immungene)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug NameCmAbs-immune effector molecule fusion (Immungene)

Drug Alias NamemAb therapeutics (Immungene)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionImmunomodulators

TargetsUpdating

Therapy Area/IndicationsAutoimmune DiseasesCommunicable Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesImmungene Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesImmungene Inc

Active IndicationsN/A

Inactive IndicationsAutoimmune DiseasesCommunicable Diseases

Other Information

ATC CodeN/A